MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Not Yet Opened 05-15 16:00:00 EDT

2.87

+0.03

+1.06%

盘后2.88

+0.01+0.35%

19:13 EDT

High2.99	Low2.84	Vol87.61K
Open2.87	D1 Closing2.84	Amplitude5.28%
Mkt Cap59.07M	Tradable Cap43.42M	Total Shares20.58M
T/O254.09K	T/O Rate0.58%	Tradable Shares15.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":2.87,"timestamp":1715803200000,"preClose":2.84,"halted":0,"volume":87611,"hourTrading":{"tag":"盘后","latestPrice":2.88,"preClose":2.87,"latestTime":"19:13 EDT","volume":252,"amount":720.84,"timestamp":1715814780783},"delay":0,"floatShares":15127332,"shares":20581469,"eps":-1.490992,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"05-15 16:00:00 EDT","open":2.87,"high":2.99,"low":2.84,"amount":254088.40591240002,"amplitude":0.052817,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.490992,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1715846400000},"marketStatusCode":0,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":2.84,"preHourTrading":{"tag":"盘前","latestPrice":2.84,"preClose":2.84,"latestTime":"09:05 EDT","volume":834,"amount":2366.511696,"timestamp":1715778301649},"postHourTrading":{"tag":"盘后","latestPrice":2.88,"preClose":2.87,"latestTime":"19:13 EDT","volume":252,"amount":720.84,"timestamp":1715814780783},"volumeRatio":0.3247547473228366},"requestUrl":"/m/hq/s/MAIA","defaultTab":"news","newsList":[{"id":"2433537987","title":"MAIA Biotechnology Unveils New Business Overview Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2433537987","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433537987?lang=en_us&edition=fundamental","pubTime":"2024-05-08 05:32","pubTimestamp":1715117550,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. (MAIA) has provided an update. MAIA Biotechnology, Inc. has released a new presentation on its business, now accessible on...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-unveils-new-business-overview-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-unveils-new-business-overview-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2431734289","title":"NKTR, IMNM and MAIA are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431734289","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431734289?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:42","pubTimestamp":1714480935,"startTime":"0","endTime":"0","summary":"Gainers: Cyclacel Pharmaceuticals Inc (CYCC) +60% FORM 10-K/A | Amended Annual Report.  Auddia Inc (AUUD) +34% Announces Strategic Product Expansion With Cloud Based Artificial Intelligence and Natura","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096200-nktr-imnm-and-maia-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431342338","title":"MAIA biotechnology announces share purchase by director in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431342338","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431342338?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:39","pubTimestamp":1714480753,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  announced that independent director Adelina Louie Ngar Yee made an individual purchase of 19,665 shares, and warrants for 19,665 shares, of MAIA’s common stock as part of recent private placement.The securities sold to the company directors participating in the offering were issued pursuant to the company’s 2021 Equity Incentive Plan.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096196-maia-biotechnology-announces-share-purchase-by-director-in-private-placement","is_publish_highlight":false,"gpt_icon":0},{"id":"2431393815","title":"MAIA Biotechnology Shares Hit 52-Week High After Director Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2431393815","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2431393815?lang=en_us&edition=fundamental","pubTime":"2024-04-30 01:04","pubTimestamp":1714410240,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology shares hit their 52-week high Monday after it said that independent director Stan Smith made an individual purchase of 147,000 shares, and warrants for 147,000 shares, as part of the company's recent private placement.The stock is up 12% to $3.30 in recent trading, and hit its 52-week high of $3.48 earlier in the session.On Thursday, the biopharmaceutical company entered into definitive agreements for the purchase and sale of 494,000 shares at $2.034 a share, in a private placement to accredited investors and certain company directors.Each share was offered together with a warrant to buy one share at an exercise price of $2.26 a share. The proceeds from the offering are $1 million, prior to offering expenses payable by the company.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2431852189","title":"MAIA Biotechnology announces share purchase by director Stan Smith in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431852189","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431852189?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:50","pubTimestamp":1714395033,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  on Monday announced that independent director Stan Smith made an individual purchase of 147,492 shares, and warrants for 147,492 shares, of MAIA’s common stock as part of the company’s recent private placement of common stock and warrants. On April 23, MAIA entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share.  Each share of common stock was offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share. The gross proceeds from the offering are about $1 million. MAIA +5.44% premarket to $3.1. Source: Press Release","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095447-maia-biotechnology-announces-share-purchase-by-director-stan-smith-in-private-placement","is_publish_highlight":false,"gpt_icon":0},{"id":"2431859080","title":"MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431859080","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2431859080?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:08","pubTimestamp":1714392480,"startTime":"0","endTime":"0","summary":"Dr. Smith has participated in every MAIA funding round. On April 23, 2024, MAIA entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock was offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share. The gross proceeds from the offering are approximately $1.0 million, prior to offering expenses payable by the Company. The securities sold to the Company directors participating in the offering were issued pursuant to the Company’s 2021 Equity Incentive Plan.MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unkn","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hv76trxqniGDVv9JbakSTg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/75604e861ada2416454d29bf94198892","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hv76trxqniGDVv9JbakSTg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/75604e861ada2416454d29bf94198892"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-share-purchase-120800051.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429194339","title":"MAIA Biotechnology Announces $1.00 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2429194339","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429194339?lang=en_us&edition=fundamental","pubTime":"2024-04-23 20:51","pubTimestamp":1713876660,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed . The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The securities being sold to the Company directors participating in the offering are being issued pursuant to the Company’s 2021 Equity Incentive Plan. The private placement is expected to close on or about April ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23100216","is_publish_highlight":false,"gpt_icon":0},{"id":"2425554692","title":"MAIA Biotechnology to Present at Two Investor Conferences in April 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2425554692","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2425554692?lang=en_us&edition=fundamental","pubTime":"2024-04-05 20:01","pubTimestamp":1712318460,"startTime":"0","endTime":"0","summary":"CHICAGO, April 05, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at two investor conferences during the month of April: the 14th Annual LD Micro Invitational taking place April 8-9, 2024, in New York City; and the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference taking place April 17-18, 2024.Early completion of enrollment; topline data expected in second half of 2024; . MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3SzwsnaUtXaqnsy1lKwpA--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0e31d067524a87064f00ac7754da3287","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3SzwsnaUtXaqnsy1lKwpA--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0e31d067524a87064f00ac7754da3287"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-present-two-investor-120100401.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424709180","title":"MAIA Biotechnology Boosts CEO Jeffrey Himmelreich’s Salary","url":"https://stock-news.laohu8.com/highlight/detail?id=2424709180","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424709180?lang=en_us&edition=fundamental","pubTime":"2024-04-03 04:22","pubTimestamp":1712089376,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. (MAIA) just unveiled an announcement. Starting April 1, 2024, Jeffrey Himmelreich’s employment agreement will see his base...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-boosts-ceo-jeffrey-himmelreichs-salary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-boosts-ceo-jeffrey-himmelreichs-salary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2423475231","title":"MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero","url":"https://stock-news.laohu8.com/highlight/detail?id=2423475231","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2423475231?lang=en_us&edition=fundamental","pubTime":"2024-03-29 03:00","pubTimestamp":1711652400,"startTime":"0","endTime":"0","summary":"Company recognizes significant support by board members in recent private placement. MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual purchases of 69,282 and 6,928 shares of common stock, respectively, as part of the Company’s recent private placement of common stock and warrants.Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer, commented, “It’s rewarding to recognize Cristian and Ramiro, along with several additional board members, for their participation in our private funding round that closed on March 11th. We consider their support as strong votes of confidence in our advancing pipeline and regulatory pathways for MAIA’s novel anti-cancer immunotherapies.”MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22995196","is_publish_highlight":false,"gpt_icon":0},{"id":"2422694425","title":"GOEV, NBSE and FLGC among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422694425","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422694425?lang=en_us&edition=fundamental","pubTime":"2024-03-26 20:15","pubTimestamp":1711455352,"startTime":"0","endTime":"0","summary":"Losers: NeuBase Therapeutics  -58%. AppTech Payments Corp  -41% announces proposed underwritten public offering. Ampio Pharmaceuticals  -38% announces voluntary delisting and SEC deregistration. Tivic Health Systems  -16% after Q3 earnings release. Cardlytics  -12% on proposed $150M convertible notes offering. Dada Nexus Ltd  -11% after Q4 earnings release.  eFFECTOR Therapeutics  -8% after Q4 earnings release. Bioline Rx Ltd  -8% after FY earnings release. MAIA Biotechnology  -7% looks to raise $1.33M through a private placement. Global Mofy Metaverse Ltd  -7%. MicroAlgo  -7%. Canoo  -6%. Flora Growth Corp  -5%. Bluebird bio  -5% reports Q4 results.   More on Pre-market losers & stocks.  Canoo: Positive News Isn't Enough Canoo: Avoid After Reverse Stock Split Canoo: There Is A Glimpse Of Hope But Hold Canoo completes acquisition of manufacturing assets from Arrival Canoo's manufacturing facility gets foreign trade zone status; shares rise ~59%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083646-goev-nbse-and-flgc-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2422691406","title":"MAIA Biotechnology looks to raise $1.33M through a private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2422691406","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422691406?lang=en_us&edition=fundamental","pubTime":"2024-03-26 20:06","pubTimestamp":1711454817,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  said it has entered into definitive agreements for the purchase and sale of an aggregate of 578.6K shares at $2.29 apiece in a private placement to raise $1.33M.The company said each share is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.55 per share.The placement is expected to close on or about March 28.More on MAIA Biotechnology  MAIA Biotechnology: Significantly Undervalued With Novel Mechanism And Impressive Early Data MAIA Biotechnology rises 3% on $2.92M private placement","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083636-maia-biotechnology-looks-to-raise-133m-through-a-private-placement","is_publish_highlight":false,"gpt_icon":0},{"id":"2422261445","title":"CGC, CYTO and IDN are among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422261445","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422261445?lang=en_us&edition=fundamental","pubTime":"2024-03-26 01:25","pubTimestamp":1711387526,"startTime":"0","endTime":"0","summary":"Gainers: Landos Biopharma  +171%. MoneyHero  +49%. Next.  +50%. KULR Technology  +42%. Intellicheck  +31%. Altamira Therapeutics  +31%. Nkarta  +26%. XTL Biopharmaceuticals  +25%. Target Hospitality  +24%. MAIA Biotechnology  +23%.  Losers: Australian Oilseeds  -29%.  Aehr Test Systems  -27%. Vimeo  -25%. flyExclusive  -24%. Invivyd  -23%. Lobo EV Technologies  -23%. TRxADE Health  -23%. Intrusion  -24%. Canopy Growth Corporation  -21%. 180 Life Sciences  -20%.   More on mid-day movers & stock  Canopy Growth Is Climbing, But It Won't Last Intellicheck, Inc.  Q4 2023 Earnings Call Transcript Canopy Growth Corporation  Q3 2024 Earnings Call Transcript Altamira stock rallies 44% on Univercells mRNA collaboration Cannabis stocks rally as Schumer circulates petition for SAFER Banking Act","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083391-cgc-cyto-and-idn-are-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2421897203","title":"MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls","url":"https://stock-news.laohu8.com/highlight/detail?id=2421897203","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2421897203?lang=en_us&edition=fundamental","pubTime":"2024-03-23 14:02","pubTimestamp":1711173748,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. (MAIA) has disclosed a new risk, in the Share Price & Shareholder Rights category. MAIA Biotechnology, Inc. faces a signif...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-at-risk-of-nyse-delisting-over-equity-shortfalls?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-at-risk-of-nyse-delisting-over-equity-shortfalls?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2421829928","title":"MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2421829928","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2421829928?lang=en_us&edition=fundamental","pubTime":"2024-03-23 03:00","pubTimestamp":1711134000,"startTime":"0","endTime":"0","summary":"Dr. Smith has participated in every MAIA funding round. MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22968301","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maiabiotech.com","stockEarnings":[{"period":"1week","weight":-0.0559},{"period":"1month","weight":0.4069},{"period":"3month","weight":0.828},{"period":"6month","weight":1.3719},{"period":"1year","weight":0.2213},{"period":"ytd","weight":1.453}],"compareEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":0.0502},{"period":"3month","weight":0.0553},{"period":"6month","weight":0.1752},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.1146}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}